The Novel Diazoxide Analog 3-Isopropylamino-7-Methoxy-4H-1,2,4-Benzothiadiazine 1,1-Dioxide Is a Selective Kir6.2/SUR1 Channel Opener
- Michael Dabrowski1,
- Frances M. Ashcroft2,
- Rebecca Ashfield2,
- Philippe Lebrun3,
- Bernard Pirotte4,
- Jan Egebjerg5,
- John Bondo Hansen1 and
- Philip Wahl1
- 1Research & Development, Novo Nordisk, Malov, Denmark
- 2University Laboratory of Physiology, Oxford, U.K
- 3Laboratory of Pharmacology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium
- 4Department of Medicinal Chemistry, Institute of Pharmacy, University of Liege, Liege, Belgium
- 5Institute of Molecular and Structural Biology, Aarhus University, Aarhus, Denmark
Abstract
ATP-sensitive K+ (KATP) channels are activated by a diverse group of compounds known as potassium channel openers (PCOs). Here, we report functional studies of the Kir6.2/SUR1 Selective PCO 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide (NNC 55-9216). We recorded cloned KATP channel currents from inside-out patches excised from Xenopus laevis oocytes heterologously expressing Kir6.2/SUR1, Kir6.2/SUR2A, or Kir6.2/SUR2B, corresponding to the β-cell, cardiac, and smooth muscle types of the KATP channel. NNC 55-9216 reversibly activated Kir6.2/SUR1 currents (EC50 = 16 μmol/l). This activation was dependent on intracellular MgATP and was abolished by mutation of a single residue in the Walker A motifs of either nucleotide-binding domain of SUR1. The drug had no effect on Kir6.2/SUR2A or Kir6.2/SUR2B currents. We therefore used chimeras of SUR1 and SUR2A to identify regions of SUR1 involved in the response to NNC 55-9216. Activation was completely abolished and significantly reduced by swapping transmembrane domains 8–11. The reverse chimera consisting of SUR2A with transmembrane domains 8–11 and NBD2 consisting SUR1 was activated by NNC 55-9216, indicating that these SUR1 regions are important for drug activation. [3H]glibenclamide binding to membranes from HEK293 cells transfected with SUR1 was displaced by NNC 55-9216 (IC50 = 105 μmol/l), and this effect was impaired when NBD2 of SUR1 was replaced by that of SUR2A. These results suggest NNC 55-9216 is a SUR1-selective PCO that requires structural determinants, which differ from those needed for activation of the KATP channel by pinacidil and cromakalim. The high selectivity of NNC 55-9216 may prove to be useful for studies of the molecular mechanism of PCO action.
Footnotes
-
Address correspondence and reprint requests to John Bondo Hansen, Novo Nordisk, Research & Development, DK 2760 Malov, Denmark. E-mail: jbha{at}novonordisk.com.
Received for publication 16 May 2001 and accepted in revised form 6 March 2002.
M.D. is currently affiliated with the University Laboratory of Physiology, Oxford, U.K. M.D. has received grant support from and holds stock in Novo Nordisk. F.M.A., P.L., and B.P. have received grant support from Novo Nordisk. J.B.H. and P.W. hold stock in Novo Nordisk.
ABC, ATP-binding cassette; KATP, ATP-sensitive K+; NBD, nucleotide-binding domain; NNC 55-9216, 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide; PCO, potassium channel opener.
- DIABETES














